nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—ABL1—liver cancer	0.39	1	CbGaD
Afatinib—HIPK4—Sorafenib—liver cancer	0.179	0.43	CbGbCtD
Afatinib—EPHA6—Sorafenib—liver cancer	0.179	0.43	CbGbCtD
Afatinib—ABCG2—Sorafenib—liver cancer	0.0265	0.0638	CbGbCtD
Afatinib—ABCG2—Doxorubicin—liver cancer	0.0161	0.0387	CbGbCtD
Afatinib—ABCB1—Sorafenib—liver cancer	0.00955	0.023	CbGbCtD
Afatinib—ABCB1—Doxorubicin—liver cancer	0.0058	0.014	CbGbCtD
Afatinib—Disease progression—Sorafenib—liver cancer	0.00423	0.0727	CcSEcCtD
Afatinib—Ventricular dysfunction—Epirubicin—liver cancer	0.00296	0.0509	CcSEcCtD
Afatinib—Ventricular dysfunction—Doxorubicin—liver cancer	0.00274	0.0471	CcSEcCtD
Afatinib—Blood potassium decreased—Sorafenib—liver cancer	0.00243	0.0418	CcSEcCtD
Afatinib—Aphthous stomatitis—Sorafenib—liver cancer	0.00197	0.0339	CcSEcCtD
Afatinib—Mucosal inflammation—Sorafenib—liver cancer	0.00167	0.0287	CcSEcCtD
Afatinib—ERBB2—gall bladder—liver cancer	0.00165	0.225	CbGeAlD
Afatinib—Interstitial lung disease—Sorafenib—liver cancer	0.0013	0.0224	CcSEcCtD
Afatinib—Rhinorrhoea—Sorafenib—liver cancer	0.00114	0.0196	CcSEcCtD
Afatinib—ERBB2—embryo—liver cancer	0.00105	0.143	CbGeAlD
Afatinib—ERBB4—embryo—liver cancer	0.00105	0.143	CbGeAlD
Afatinib—Vandetanib—ABL1—liver cancer	0.00098	0.305	CrCbGaD
Afatinib—Mouth ulceration—Sorafenib—liver cancer	0.000835	0.0144	CcSEcCtD
Afatinib—Vandetanib—KDR—liver cancer	0.000834	0.259	CrCbGaD
Afatinib—Aphthous stomatitis—Epirubicin—liver cancer	0.000728	0.0125	CcSEcCtD
Afatinib—Vandetanib—VEGFA—liver cancer	0.000707	0.22	CrCbGaD
Afatinib—Aphthous stomatitis—Doxorubicin—liver cancer	0.000673	0.0116	CcSEcCtD
Afatinib—Dehydration—Sorafenib—liver cancer	0.000623	0.0107	CcSEcCtD
Afatinib—Mucosal inflammation—Epirubicin—liver cancer	0.000616	0.0106	CcSEcCtD
Afatinib—Dry skin—Sorafenib—liver cancer	0.000614	0.0106	CcSEcCtD
Afatinib—Hypokalaemia—Sorafenib—liver cancer	0.00061	0.0105	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Sorafenib—liver cancer	0.000603	0.0104	CcSEcCtD
Afatinib—Nasopharyngitis—Sorafenib—liver cancer	0.000599	0.0103	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Sorafenib—liver cancer	0.000591	0.0102	CcSEcCtD
Afatinib—Mucosal inflammation—Doxorubicin—liver cancer	0.00057	0.00981	CcSEcCtD
Afatinib—PHKG2—liver—liver cancer	0.000538	0.0735	CbGeAlD
Afatinib—Keratitis—Epirubicin—liver cancer	0.000526	0.00905	CcSEcCtD
Afatinib—Weight decreased—Sorafenib—liver cancer	0.000524	0.00902	CcSEcCtD
Afatinib—Pneumonia—Sorafenib—liver cancer	0.000519	0.00894	CcSEcCtD
Afatinib—Infestation NOS—Sorafenib—liver cancer	0.000516	0.00888	CcSEcCtD
Afatinib—Infestation—Sorafenib—liver cancer	0.000516	0.00888	CcSEcCtD
Afatinib—Renal failure—Sorafenib—liver cancer	0.000508	0.00873	CcSEcCtD
Afatinib—Stomatitis—Sorafenib—liver cancer	0.000503	0.00866	CcSEcCtD
Afatinib—Hepatobiliary disease—Sorafenib—liver cancer	0.000488	0.0084	CcSEcCtD
Afatinib—Epistaxis—Sorafenib—liver cancer	0.000487	0.00838	CcSEcCtD
Afatinib—Keratitis—Doxorubicin—liver cancer	0.000487	0.00837	CcSEcCtD
Afatinib—ERBB2—liver—liver cancer	0.000484	0.0661	CbGeAlD
Afatinib—DYRK1A—liver—liver cancer	0.000466	0.0636	CbGeAlD
Afatinib—Urinary tract disorder—Sorafenib—liver cancer	0.000458	0.00788	CcSEcCtD
Afatinib—Connective tissue disorder—Sorafenib—liver cancer	0.000456	0.00784	CcSEcCtD
Afatinib—Urethral disorder—Sorafenib—liver cancer	0.000454	0.00782	CcSEcCtD
Afatinib—ABL1—embryo—liver cancer	0.000438	0.0599	CbGeAlD
Afatinib—Mediastinal disorder—Sorafenib—liver cancer	0.000418	0.00719	CcSEcCtD
Afatinib—EGFR—liver—liver cancer	0.00041	0.056	CbGeAlD
Afatinib—Alopecia—Sorafenib—liver cancer	0.00041	0.00705	CcSEcCtD
Afatinib—Mental disorder—Sorafenib—liver cancer	0.000406	0.00699	CcSEcCtD
Afatinib—Malnutrition—Sorafenib—liver cancer	0.000404	0.00694	CcSEcCtD
Afatinib—Dysgeusia—Sorafenib—liver cancer	0.000395	0.0068	CcSEcCtD
Afatinib—Muscle spasms—Sorafenib—liver cancer	0.000388	0.00668	CcSEcCtD
Afatinib—IRAK1—liver—liver cancer	0.000362	0.0494	CbGeAlD
Afatinib—LCK—liver—liver cancer	0.000353	0.0482	CbGeAlD
Afatinib—Cough—Sorafenib—liver cancer	0.000352	0.00606	CcSEcCtD
Afatinib—DYRK1A—Daunorubicin—Epirubicin—liver cancer	0.000341	0.0946	CbGdCrCtD
Afatinib—DYRK1A—Idarubicin—Epirubicin—liver cancer	0.000341	0.0946	CbGdCrCtD
Afatinib—DYRK1A—Doxorubicin—Epirubicin—liver cancer	0.000341	0.0946	CbGdCrCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.000341	0.00587	CcSEcCtD
Afatinib—Cystitis noninfective—Epirubicin—liver cancer	0.000333	0.00573	CcSEcCtD
Afatinib—Cystitis—Epirubicin—liver cancer	0.000329	0.00567	CcSEcCtD
Afatinib—Infection—Sorafenib—liver cancer	0.000327	0.00563	CcSEcCtD
Afatinib—Gefitinib—CYP1A1—liver cancer	0.000324	0.101	CrCbGaD
Afatinib—Nervous system disorder—Sorafenib—liver cancer	0.000323	0.00556	CcSEcCtD
Afatinib—Skin disorder—Sorafenib—liver cancer	0.00032	0.0055	CcSEcCtD
Afatinib—DYRK1A—Idarubicin—Doxorubicin—liver cancer	0.000316	0.0875	CbGdCrCtD
Afatinib—DYRK1A—Epirubicin—Doxorubicin—liver cancer	0.000316	0.0875	CbGdCrCtD
Afatinib—DYRK1A—Daunorubicin—Doxorubicin—liver cancer	0.000316	0.0875	CbGdCrCtD
Afatinib—Dry eye—Epirubicin—liver cancer	0.000315	0.00542	CcSEcCtD
Afatinib—Mouth ulceration—Epirubicin—liver cancer	0.000308	0.00531	CcSEcCtD
Afatinib—Bladder pain—Epirubicin—liver cancer	0.000308	0.00531	CcSEcCtD
Afatinib—Cystitis noninfective—Doxorubicin—liver cancer	0.000308	0.0053	CcSEcCtD
Afatinib—Cystitis—Doxorubicin—liver cancer	0.000305	0.00524	CcSEcCtD
Afatinib—Sepsis—Epirubicin—liver cancer	0.000296	0.00509	CcSEcCtD
Afatinib—Dyspnoea—Sorafenib—liver cancer	0.000294	0.00505	CcSEcCtD
Afatinib—Dry eye—Doxorubicin—liver cancer	0.000292	0.00502	CcSEcCtD
Afatinib—Dyspepsia—Sorafenib—liver cancer	0.00029	0.00499	CcSEcCtD
Afatinib—Decreased appetite—Sorafenib—liver cancer	0.000286	0.00493	CcSEcCtD
Afatinib—Mouth ulceration—Doxorubicin—liver cancer	0.000285	0.00491	CcSEcCtD
Afatinib—Bladder pain—Doxorubicin—liver cancer	0.000285	0.00491	CcSEcCtD
Afatinib—Gastrointestinal disorder—Sorafenib—liver cancer	0.000284	0.00489	CcSEcCtD
Afatinib—Fatigue—Sorafenib—liver cancer	0.000284	0.00489	CcSEcCtD
Afatinib—Constipation—Sorafenib—liver cancer	0.000282	0.00485	CcSEcCtD
Afatinib—Sepsis—Doxorubicin—liver cancer	0.000274	0.00471	CcSEcCtD
Afatinib—ERBB2—Doxorubicin—Epirubicin—liver cancer	0.000263	0.0728	CbGdCrCtD
Afatinib—Body temperature increased—Sorafenib—liver cancer	0.00026	0.00448	CcSEcCtD
Afatinib—Renal impairment—Epirubicin—liver cancer	0.00026	0.00448	CcSEcCtD
Afatinib—ERBB2—Epirubicin—Doxorubicin—liver cancer	0.000243	0.0673	CbGdCrCtD
Afatinib—Renal impairment—Doxorubicin—liver cancer	0.000241	0.00414	CcSEcCtD
Afatinib—Asthenia—Sorafenib—liver cancer	0.000236	0.00407	CcSEcCtD
Afatinib—Pruritus—Sorafenib—liver cancer	0.000233	0.00401	CcSEcCtD
Afatinib—Dehydration—Epirubicin—liver cancer	0.00023	0.00396	CcSEcCtD
Afatinib—Dry skin—Epirubicin—liver cancer	0.000227	0.00391	CcSEcCtD
Afatinib—Hypokalaemia—Epirubicin—liver cancer	0.000225	0.00388	CcSEcCtD
Afatinib—Diarrhoea—Sorafenib—liver cancer	0.000225	0.00388	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.000223	0.00384	CcSEcCtD
Afatinib—Nasopharyngitis—Epirubicin—liver cancer	0.000221	0.00381	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Epirubicin—liver cancer	0.000218	0.00376	CcSEcCtD
Afatinib—Dizziness—Sorafenib—liver cancer	0.000218	0.00375	CcSEcCtD
Afatinib—Dehydration—Doxorubicin—liver cancer	0.000213	0.00367	CcSEcCtD
Afatinib—Dry skin—Doxorubicin—liver cancer	0.00021	0.00361	CcSEcCtD
Afatinib—Vomiting—Sorafenib—liver cancer	0.000209	0.0036	CcSEcCtD
Afatinib—Hypokalaemia—Doxorubicin—liver cancer	0.000209	0.00359	CcSEcCtD
Afatinib—Rash—Sorafenib—liver cancer	0.000208	0.00357	CcSEcCtD
Afatinib—Dermatitis—Sorafenib—liver cancer	0.000207	0.00357	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.000206	0.00355	CcSEcCtD
Afatinib—Headache—Sorafenib—liver cancer	0.000206	0.00355	CcSEcCtD
Afatinib—Nasopharyngitis—Doxorubicin—liver cancer	0.000205	0.00353	CcSEcCtD
Afatinib—ABL1—liver—liver cancer	0.000203	0.0277	CbGeAlD
Afatinib—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.000202	0.00348	CcSEcCtD
Afatinib—Upper respiratory tract infection—Epirubicin—liver cancer	0.000199	0.00342	CcSEcCtD
Afatinib—ABL1—Doxorubicin—Epirubicin—liver cancer	0.000196	0.0543	CbGdCrCtD
Afatinib—ABL1—Idarubicin—Epirubicin—liver cancer	0.000196	0.0543	CbGdCrCtD
Afatinib—ABL1—Daunorubicin—Epirubicin—liver cancer	0.000196	0.0543	CbGdCrCtD
Afatinib—Nausea—Sorafenib—liver cancer	0.000196	0.00337	CcSEcCtD
Afatinib—Weight decreased—Epirubicin—liver cancer	0.000194	0.00333	CcSEcCtD
Afatinib—Pneumonia—Epirubicin—liver cancer	0.000192	0.0033	CcSEcCtD
Afatinib—Infestation NOS—Epirubicin—liver cancer	0.000191	0.00328	CcSEcCtD
Afatinib—Infestation—Epirubicin—liver cancer	0.000191	0.00328	CcSEcCtD
Afatinib—Vandetanib—ALB—liver cancer	0.00019	0.0591	CrCbGaD
Afatinib—Renal failure—Epirubicin—liver cancer	0.000188	0.00323	CcSEcCtD
Afatinib—Stomatitis—Epirubicin—liver cancer	0.000186	0.0032	CcSEcCtD
Afatinib—Urinary tract infection—Epirubicin—liver cancer	0.000185	0.00319	CcSEcCtD
Afatinib—Conjunctivitis—Epirubicin—liver cancer	0.000185	0.00319	CcSEcCtD
Afatinib—Upper respiratory tract infection—Doxorubicin—liver cancer	0.000184	0.00317	CcSEcCtD
Afatinib—ABL1—Epirubicin—Doxorubicin—liver cancer	0.000181	0.0503	CbGdCrCtD
Afatinib—ABL1—Idarubicin—Doxorubicin—liver cancer	0.000181	0.0503	CbGdCrCtD
Afatinib—ABL1—Daunorubicin—Doxorubicin—liver cancer	0.000181	0.0503	CbGdCrCtD
Afatinib—Gefitinib—ALB—liver cancer	0.00018	0.0561	CrCbGaD
Afatinib—Hepatobiliary disease—Epirubicin—liver cancer	0.00018	0.00311	CcSEcCtD
Afatinib—Epistaxis—Epirubicin—liver cancer	0.00018	0.0031	CcSEcCtD
Afatinib—Weight decreased—Doxorubicin—liver cancer	0.000179	0.00308	CcSEcCtD
Afatinib—Pneumonia—Doxorubicin—liver cancer	0.000178	0.00306	CcSEcCtD
Afatinib—Infestation NOS—Doxorubicin—liver cancer	0.000177	0.00304	CcSEcCtD
Afatinib—Infestation—Doxorubicin—liver cancer	0.000177	0.00304	CcSEcCtD
Afatinib—Renal failure—Doxorubicin—liver cancer	0.000174	0.00299	CcSEcCtD
Afatinib—Stomatitis—Doxorubicin—liver cancer	0.000172	0.00296	CcSEcCtD
Afatinib—Conjunctivitis—Doxorubicin—liver cancer	0.000172	0.00295	CcSEcCtD
Afatinib—Urinary tract infection—Doxorubicin—liver cancer	0.000172	0.00295	CcSEcCtD
Afatinib—Urinary tract disorder—Epirubicin—liver cancer	0.000169	0.00291	CcSEcCtD
Afatinib—Connective tissue disorder—Epirubicin—liver cancer	0.000168	0.0029	CcSEcCtD
Afatinib—Urethral disorder—Epirubicin—liver cancer	0.000168	0.00289	CcSEcCtD
Afatinib—Hepatobiliary disease—Doxorubicin—liver cancer	0.000167	0.00287	CcSEcCtD
Afatinib—Epistaxis—Doxorubicin—liver cancer	0.000167	0.00287	CcSEcCtD
Afatinib—Eye disorder—Epirubicin—liver cancer	0.00016	0.00275	CcSEcCtD
Afatinib—Urinary tract disorder—Doxorubicin—liver cancer	0.000157	0.00269	CcSEcCtD
Afatinib—Connective tissue disorder—Doxorubicin—liver cancer	0.000156	0.00268	CcSEcCtD
Afatinib—Urethral disorder—Doxorubicin—liver cancer	0.000155	0.00267	CcSEcCtD
Afatinib—Mediastinal disorder—Epirubicin—liver cancer	0.000154	0.00266	CcSEcCtD
Afatinib—Alopecia—Epirubicin—liver cancer	0.000151	0.0026	CcSEcCtD
Afatinib—Mental disorder—Epirubicin—liver cancer	0.00015	0.00258	CcSEcCtD
Afatinib—Malnutrition—Epirubicin—liver cancer	0.000149	0.00257	CcSEcCtD
Afatinib—Eye disorder—Doxorubicin—liver cancer	0.000148	0.00255	CcSEcCtD
Afatinib—Dysgeusia—Epirubicin—liver cancer	0.000146	0.00251	CcSEcCtD
Afatinib—Back pain—Epirubicin—liver cancer	0.000144	0.00248	CcSEcCtD
Afatinib—Muscle spasms—Epirubicin—liver cancer	0.000143	0.00247	CcSEcCtD
Afatinib—Mediastinal disorder—Doxorubicin—liver cancer	0.000143	0.00246	CcSEcCtD
Afatinib—Alopecia—Doxorubicin—liver cancer	0.00014	0.00241	CcSEcCtD
Afatinib—Mental disorder—Doxorubicin—liver cancer	0.000139	0.00239	CcSEcCtD
Afatinib—Malnutrition—Doxorubicin—liver cancer	0.000138	0.00237	CcSEcCtD
Afatinib—ABCB1—embryo—liver cancer	0.000136	0.0186	CbGeAlD
Afatinib—Dysgeusia—Doxorubicin—liver cancer	0.000135	0.00232	CcSEcCtD
Afatinib—Back pain—Doxorubicin—liver cancer	0.000133	0.0023	CcSEcCtD
Afatinib—Muscle spasms—Doxorubicin—liver cancer	0.000133	0.00228	CcSEcCtD
Afatinib—Cough—Epirubicin—liver cancer	0.00013	0.00224	CcSEcCtD
Afatinib—ABCG2—liver—liver cancer	0.000128	0.0175	CbGeAlD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000126	0.00217	CcSEcCtD
Afatinib—Infection—Epirubicin—liver cancer	0.000121	0.00208	CcSEcCtD
Afatinib—Cough—Doxorubicin—liver cancer	0.00012	0.00207	CcSEcCtD
Afatinib—Nervous system disorder—Epirubicin—liver cancer	0.000119	0.00205	CcSEcCtD
Afatinib—Skin disorder—Epirubicin—liver cancer	0.000118	0.00203	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000117	0.00201	CcSEcCtD
Afatinib—Infection—Doxorubicin—liver cancer	0.000112	0.00193	CcSEcCtD
Afatinib—Nervous system disorder—Doxorubicin—liver cancer	0.00011	0.0019	CcSEcCtD
Afatinib—Insomnia—Epirubicin—liver cancer	0.00011	0.00189	CcSEcCtD
Afatinib—Skin disorder—Doxorubicin—liver cancer	0.000109	0.00188	CcSEcCtD
Afatinib—Dyspnoea—Epirubicin—liver cancer	0.000109	0.00187	CcSEcCtD
Afatinib—Dyspepsia—Epirubicin—liver cancer	0.000107	0.00184	CcSEcCtD
Afatinib—Decreased appetite—Epirubicin—liver cancer	0.000106	0.00182	CcSEcCtD
Afatinib—Gastrointestinal disorder—Epirubicin—liver cancer	0.000105	0.00181	CcSEcCtD
Afatinib—Fatigue—Epirubicin—liver cancer	0.000105	0.00181	CcSEcCtD
Afatinib—Constipation—Epirubicin—liver cancer	0.000104	0.00179	CcSEcCtD
Afatinib—Insomnia—Doxorubicin—liver cancer	0.000102	0.00175	CcSEcCtD
Afatinib—Dyspnoea—Doxorubicin—liver cancer	0.0001	0.00173	CcSEcCtD
Afatinib—Dyspepsia—Doxorubicin—liver cancer	9.91e-05	0.00171	CcSEcCtD
Afatinib—Decreased appetite—Doxorubicin—liver cancer	9.79e-05	0.00168	CcSEcCtD
Afatinib—Gastrointestinal disorder—Doxorubicin—liver cancer	9.72e-05	0.00167	CcSEcCtD
Afatinib—Fatigue—Doxorubicin—liver cancer	9.71e-05	0.00167	CcSEcCtD
Afatinib—Constipation—Doxorubicin—liver cancer	9.63e-05	0.00166	CcSEcCtD
Afatinib—Body temperature increased—Epirubicin—liver cancer	9.62e-05	0.00166	CcSEcCtD
Afatinib—Body temperature increased—Doxorubicin—liver cancer	8.9e-05	0.00153	CcSEcCtD
Afatinib—Asthenia—Epirubicin—liver cancer	8.73e-05	0.0015	CcSEcCtD
Afatinib—Pruritus—Epirubicin—liver cancer	8.61e-05	0.00148	CcSEcCtD
Afatinib—Diarrhoea—Epirubicin—liver cancer	8.33e-05	0.00143	CcSEcCtD
Afatinib—Asthenia—Doxorubicin—liver cancer	8.08e-05	0.00139	CcSEcCtD
Afatinib—Dizziness—Epirubicin—liver cancer	8.05e-05	0.00138	CcSEcCtD
Afatinib—Pruritus—Doxorubicin—liver cancer	7.97e-05	0.00137	CcSEcCtD
Afatinib—Vomiting—Epirubicin—liver cancer	7.74e-05	0.00133	CcSEcCtD
Afatinib—Diarrhoea—Doxorubicin—liver cancer	7.71e-05	0.00133	CcSEcCtD
Afatinib—Rash—Epirubicin—liver cancer	7.67e-05	0.00132	CcSEcCtD
Afatinib—Dermatitis—Epirubicin—liver cancer	7.67e-05	0.00132	CcSEcCtD
Afatinib—Headache—Epirubicin—liver cancer	7.62e-05	0.00131	CcSEcCtD
Afatinib—Dizziness—Doxorubicin—liver cancer	7.45e-05	0.00128	CcSEcCtD
Afatinib—Nausea—Epirubicin—liver cancer	7.23e-05	0.00124	CcSEcCtD
Afatinib—Vomiting—Doxorubicin—liver cancer	7.16e-05	0.00123	CcSEcCtD
Afatinib—Rash—Doxorubicin—liver cancer	7.1e-05	0.00122	CcSEcCtD
Afatinib—Dermatitis—Doxorubicin—liver cancer	7.09e-05	0.00122	CcSEcCtD
Afatinib—Headache—Doxorubicin—liver cancer	7.06e-05	0.00121	CcSEcCtD
Afatinib—Nausea—Doxorubicin—liver cancer	6.69e-05	0.00115	CcSEcCtD
Afatinib—ABCB1—liver—liver cancer	6.3e-05	0.00861	CbGeAlD
Afatinib—ABL1—Immune System—IL2—liver cancer	4.03e-06	3.29e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—H2AFX—liver cancer	4e-06	3.27e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—HRAS—liver cancer	3.98e-06	3.25e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PIK3CD—liver cancer	3.97e-06	3.24e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—IL6—liver cancer	3.97e-06	3.24e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—KRAS—liver cancer	3.96e-06	3.23e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—IL6—liver cancer	3.94e-06	3.21e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—SERPINE1—liver cancer	3.93e-06	3.21e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—PIK3CA—liver cancer	3.93e-06	3.2e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—JUN—liver cancer	3.92e-06	3.2e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	3.92e-06	3.2e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—VEGFA—liver cancer	3.92e-06	3.19e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—CTNNB1—liver cancer	3.89e-06	3.17e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—HRAS—liver cancer	3.89e-06	3.17e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—STAT3—liver cancer	3.88e-06	3.16e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—IL6—liver cancer	3.87e-06	3.15e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—AKT1—liver cancer	3.87e-06	3.15e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—VEGFA—liver cancer	3.86e-06	3.15e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—RAF1—liver cancer	3.84e-06	3.13e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PIK3CD—liver cancer	3.83e-06	3.12e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—STAT3—liver cancer	3.82e-06	3.11e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—IL6—liver cancer	3.81e-06	3.11e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—AKT1—liver cancer	3.81e-06	3.1e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—CDKN1A—liver cancer	3.8e-06	3.1e-05	CbGpPWpGaD
Afatinib—LCK—Disease—SERPINE1—liver cancer	3.79e-06	3.09e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—PIK3CA—liver cancer	3.78e-06	3.09e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—IL2—liver cancer	3.77e-06	3.08e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—PIK3CA—liver cancer	3.77e-06	3.08e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TERT—liver cancer	3.76e-06	3.06e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—AKT1—liver cancer	3.75e-06	3.06e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—MTOR—liver cancer	3.75e-06	3.06e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—PIK3CB—liver cancer	3.75e-06	3.06e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—KRAS—liver cancer	3.72e-06	3.04e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—RAF1—liver cancer	3.72e-06	3.03e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PSMD10—liver cancer	3.71e-06	3.03e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PSMA4—liver cancer	3.71e-06	3.03e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—MAPK8—liver cancer	3.71e-06	3.03e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—RAF1—liver cancer	3.7e-06	3.02e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—AKT1—liver cancer	3.66e-06	2.99e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—PIK3CA—liver cancer	3.63e-06	2.96e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—HRAS—liver cancer	3.63e-06	2.96e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—AKT1—liver cancer	3.63e-06	2.96e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MTOR—liver cancer	3.63e-06	2.96e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PIK3CB—liver cancer	3.63e-06	2.96e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TERT—liver cancer	3.62e-06	2.95e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—MTOR—liver cancer	3.62e-06	2.95e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—PIK3CB—liver cancer	3.62e-06	2.95e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GOT2—liver cancer	3.61e-06	2.95e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MYC—liver cancer	3.6e-06	2.94e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TGFB1—liver cancer	3.59e-06	2.93e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—AKT1—liver cancer	3.57e-06	2.91e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MYC—liver cancer	3.55e-06	2.89e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—RAF1—liver cancer	3.55e-06	2.89e-05	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—ALB—liver cancer	3.54e-06	2.89e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TGFB1—liver cancer	3.54e-06	2.89e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CG—liver cancer	3.53e-06	2.88e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CDKN1B—liver cancer	3.52e-06	2.87e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—AKT1—liver cancer	3.52e-06	2.87e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—HRAS—liver cancer	3.5e-06	2.86e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—HRAS—liver cancer	3.49e-06	2.85e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—IL6—liver cancer	3.48e-06	2.84e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—MTOR—liver cancer	3.46e-06	2.82e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PIK3CB—liver cancer	3.46e-06	2.82e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL2—liver cancer	3.45e-06	2.81e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—KDR—liver cancer	3.44e-06	2.8e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—AKT1—liver cancer	3.43e-06	2.8e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—PIK3CA—liver cancer	3.42e-06	2.79e-05	CbGpPWpGaD
Afatinib—LCK—Disease—RAF1—liver cancer	3.42e-06	2.79e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MAPK14—liver cancer	3.41e-06	2.78e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PPARG—liver cancer	3.41e-06	2.78e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CDKN1B—liver cancer	3.4e-06	2.78e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYP2E1—liver cancer	3.4e-06	2.77e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—STAT3—liver cancer	3.39e-06	2.77e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CDKN1B—liver cancer	3.39e-06	2.77e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—HRAS—liver cancer	3.36e-06	2.74e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—JUN—liver cancer	3.35e-06	2.73e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—IL6—liver cancer	3.35e-06	2.73e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—ESR1—liver cancer	3.35e-06	2.73e-05	CbGpPWpGaD
Afatinib—LCK—Disease—MTOR—liver cancer	3.34e-06	2.72e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PIK3CB—liver cancer	3.34e-06	2.72e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CASP3—liver cancer	3.34e-06	2.72e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL2—liver cancer	3.33e-06	2.72e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—KRAS—liver cancer	3.33e-06	2.72e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CTNNB1—liver cancer	3.33e-06	2.71e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IL2—liver cancer	3.32e-06	2.71e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—KDR—liver cancer	3.31e-06	2.7e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—F2—liver cancer	3.31e-06	2.7e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MAPK14—liver cancer	3.29e-06	2.68e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—KRAS—liver cancer	3.28e-06	2.67e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—CDKN1B—liver cancer	3.25e-06	2.65e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CDKN1A—liver cancer	3.25e-06	2.65e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CCND1—liver cancer	3.25e-06	2.65e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—JUN—liver cancer	3.24e-06	2.64e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—JUN—liver cancer	3.23e-06	2.63e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—ESR1—liver cancer	3.23e-06	2.63e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CTNNB1—liver cancer	3.22e-06	2.62e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—AKT1—liver cancer	3.21e-06	2.62e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CTNNB1—liver cancer	3.21e-06	2.61e-05	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—RAF1—liver cancer	3.2e-06	2.61e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—F2—liver cancer	3.19e-06	2.6e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYCS—liver cancer	3.18e-06	2.59e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—MAPK8—liver cancer	3.17e-06	2.59e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CG—liver cancer	3.17e-06	2.58e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—APC—liver cancer	3.17e-06	2.58e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—HRAS—liver cancer	3.16e-06	2.58e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MMP9—liver cancer	3.15e-06	2.57e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CDKN1A—liver cancer	3.14e-06	2.56e-05	CbGpPWpGaD
Afatinib—LCK—Disease—CDKN1B—liver cancer	3.13e-06	2.55e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CDKN1A—liver cancer	3.13e-06	2.55e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GOT1—liver cancer	3.12e-06	2.54e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GGT1—liver cancer	3.12e-06	2.54e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CD—liver cancer	3.11e-06	2.53e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—AKT1—liver cancer	3.09e-06	2.52e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—AKT1—liver cancer	3.08e-06	2.51e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—CTNNB1—liver cancer	3.07e-06	2.5e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—ALB—liver cancer	3.07e-06	2.5e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MAPK8—liver cancer	3.07e-06	2.5e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—PIK3CA—liver cancer	3.06e-06	2.49e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—MAPK8—liver cancer	3.06e-06	2.49e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CG—liver cancer	3.05e-06	2.49e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—APC—liver cancer	3.05e-06	2.49e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IL6—liver cancer	3.03e-06	2.47e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—PIK3CA—liver cancer	3.01e-06	2.46e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—CDKN1A—liver cancer	3e-06	2.45e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—BRAF—liver cancer	2.98e-06	2.43e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—AKT1—liver cancer	2.97e-06	2.42e-05	CbGpPWpGaD
Afatinib—LCK—Disease—CTNNB1—liver cancer	2.96e-06	2.41e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TP53—liver cancer	2.96e-06	2.41e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TP53—liver cancer	2.91e-06	2.38e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—KRAS—liver cancer	2.91e-06	2.38e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—STAT3—liver cancer	2.9e-06	2.36e-05	CbGpPWpGaD
Afatinib—LCK—Disease—CDKN1A—liver cancer	2.89e-06	2.36e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—BRAF—liver cancer	2.87e-06	2.34e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—VEGFA—liver cancer	2.83e-06	2.31e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—HRAS—liver cancer	2.83e-06	2.31e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—STAT3—liver cancer	2.8e-06	2.29e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GSTP1—liver cancer	2.8e-06	2.28e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—AKT1—liver cancer	2.79e-06	2.28e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—STAT3—liver cancer	2.79e-06	2.28e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—HRAS—liver cancer	2.79e-06	2.27e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CD—liver cancer	2.78e-06	2.27e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—HMOX1—liver cancer	2.76e-06	2.25e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—SERPINE1—liver cancer	2.75e-06	2.24e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—KRAS—liver cancer	2.72e-06	2.22e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—IL6—liver cancer	2.71e-06	2.21e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CB—liver cancer	2.71e-06	2.21e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CD—liver cancer	2.68e-06	2.19e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—STAT3—liver cancer	2.68e-06	2.18e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—PIK3CA—liver cancer	2.68e-06	2.18e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—IL6—liver cancer	2.67e-06	2.18e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—SERPINE1—liver cancer	2.65e-06	2.16e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MYC—liver cancer	2.61e-06	2.12e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TGFB1—liver cancer	2.6e-06	2.12e-05	CbGpPWpGaD
Afatinib—LCK—Disease—STAT3—liver cancer	2.58e-06	2.1e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GSTM1—liver cancer	2.57e-06	2.1e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—PIK3CA—liver cancer	2.5e-06	2.04e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—AKT1—liver cancer	2.5e-06	2.04e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—KRAS—liver cancer	2.49e-06	2.03e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—MYC—liver cancer	2.49e-06	2.03e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—RAF1—liver cancer	2.48e-06	2.03e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—TGFB1—liver cancer	2.48e-06	2.02e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—HRAS—liver cancer	2.48e-06	2.02e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—AKT1—liver cancer	2.46e-06	2.01e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYP1A1—liver cancer	2.44e-06	1.99e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MTOR—liver cancer	2.43e-06	1.98e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CB—liver cancer	2.43e-06	1.98e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—KRAS—liver cancer	2.41e-06	1.96e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—KRAS—liver cancer	2.4e-06	1.96e-05	CbGpPWpGaD
Afatinib—LCK—Disease—MYC—liver cancer	2.4e-06	1.95e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—RAF1—liver cancer	2.39e-06	1.95e-05	CbGpPWpGaD
Afatinib—LCK—Disease—TGFB1—liver cancer	2.39e-06	1.95e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL6—liver cancer	2.37e-06	1.93e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MTOR—liver cancer	2.34e-06	1.91e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CB—liver cancer	2.34e-06	1.91e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—HRAS—liver cancer	2.32e-06	1.89e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—KRAS—liver cancer	2.3e-06	1.87e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—PIK3CA—liver cancer	2.29e-06	1.87e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CDKN1B—liver cancer	2.28e-06	1.86e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—MTHFR—liver cancer	2.27e-06	1.85e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PPARA—liver cancer	2.23e-06	1.82e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CASP3—liver cancer	2.23e-06	1.82e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL2—liver cancer	2.23e-06	1.82e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—IL6—liver cancer	2.22e-06	1.81e-05	CbGpPWpGaD
Afatinib—LCK—Disease—KRAS—liver cancer	2.22e-06	1.81e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PIK3CA—liver cancer	2.21e-06	1.8e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—PIK3CA—liver cancer	2.2e-06	1.8e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CDKN1B—liver cancer	2.19e-06	1.79e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—AKT1—liver cancer	2.19e-06	1.78e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCND1—liver cancer	2.17e-06	1.77e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—JUN—liver cancer	2.17e-06	1.77e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CTNNB1—liver cancer	2.15e-06	1.75e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CASP3—liver cancer	2.15e-06	1.75e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL2—liver cancer	2.15e-06	1.75e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TP53—liver cancer	2.14e-06	1.74e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—HRAS—liver cancer	2.12e-06	1.73e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PIK3CA—liver cancer	2.11e-06	1.72e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MMP9—liver cancer	2.11e-06	1.72e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CDKN1A—liver cancer	2.1e-06	1.71e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCND1—liver cancer	2.09e-06	1.71e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—JUN—liver cancer	2.09e-06	1.7e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CTNNB1—liver cancer	2.07e-06	1.69e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MAPK8—liver cancer	2.05e-06	1.67e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—HRAS—liver cancer	2.05e-06	1.67e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—AKT1—liver cancer	2.05e-06	1.67e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—HRAS—liver cancer	2.04e-06	1.66e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PIK3CA—liver cancer	2.04e-06	1.66e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MMP9—liver cancer	2.03e-06	1.66e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL6—liver cancer	2.03e-06	1.65e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CDKN1A—liver cancer	2.02e-06	1.65e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MAPK8—liver cancer	1.98e-06	1.61e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL6—liver cancer	1.96e-06	1.6e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—HRAS—liver cancer	1.95e-06	1.59e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IL6—liver cancer	1.95e-06	1.59e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CG—liver cancer	1.91e-06	1.56e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—VEGFA—liver cancer	1.89e-06	1.54e-05	CbGpPWpGaD
Afatinib—LCK—Disease—HRAS—liver cancer	1.88e-06	1.54e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—STAT3—liver cancer	1.87e-06	1.53e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—IL6—liver cancer	1.87e-06	1.52e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—AKT1—liver cancer	1.87e-06	1.52e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PPARG—liver cancer	1.84e-06	1.5e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—VEGFA—liver cancer	1.82e-06	1.49e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—AKT1—liver cancer	1.81e-06	1.47e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—STAT3—liver cancer	1.81e-06	1.47e-05	CbGpPWpGaD
Afatinib—LCK—Disease—IL6—liver cancer	1.8e-06	1.47e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—AKT1—liver cancer	1.8e-06	1.47e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MYC—liver cancer	1.74e-06	1.42e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TGFB1—liver cancer	1.74e-06	1.42e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—AKT1—liver cancer	1.73e-06	1.41e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CD—liver cancer	1.68e-06	1.37e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MYC—liver cancer	1.68e-06	1.37e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TGFB1—liver cancer	1.67e-06	1.37e-05	CbGpPWpGaD
Afatinib—LCK—Disease—AKT1—liver cancer	1.66e-06	1.36e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ALB—liver cancer	1.66e-06	1.35e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CA—liver cancer	1.65e-06	1.35e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—KRAS—liver cancer	1.61e-06	1.31e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—KRAS—liver cancer	1.55e-06	1.26e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CA—liver cancer	1.48e-06	1.21e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CB—liver cancer	1.46e-06	1.19e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TP53—liver cancer	1.43e-06	1.17e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CA—liver cancer	1.43e-06	1.16e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TP53—liver cancer	1.38e-06	1.12e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—HRAS—liver cancer	1.37e-06	1.12e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—AKT1—liver cancer	1.35e-06	1.1e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—HRAS—liver cancer	1.32e-06	1.08e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL6—liver cancer	1.31e-06	1.07e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL6—liver cancer	1.26e-06	1.03e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—AKT1—liver cancer	1.21e-06	9.85e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—AKT1—liver cancer	1.16e-06	9.49e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CA—liver cancer	8.93e-07	7.28e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—AKT1—liver cancer	7.29e-07	5.95e-06	CbGpPWpGaD
